Fasenra is a biologic medication classified as a monoclonal antibody [1]. Specifically, it is a humanized immunoglobulin G1 kappa (IgG1κ) monoclonal antibody [2].
What is Fasenra used to treat?
Fasenra is approved for the add-on maintenance treatment of adult patients with severe eosinophilic asthma who have an as-of-right eosinophilic phenotype [1][3]. It targets the alpha subunit of the interleukin-5 (IL-5) receptor on eosinophils, basophils, and eosinophilic lineage cells [2][4]. By inhibiting IL-5 signaling, Fasenra reduces the number of eosinophils in the blood and lungs [4].
How does Fasenra work?
Fasenra works by binding to the IL-5 receptor alpha (IL-5Rα) on the surface of eosinophils and basophils. This binding prevents IL-5 from attaching to its receptor, thereby blocking the signaling pathway that promotes eosinophil survival, activation, and recruitment [2][4]. This targeted approach aims to reduce the underlying inflammation associated with eosinophilic asthma [4].
When does Fasenra's patent expire?
The patent expiration dates for Fasenra can be complex, often involving multiple patents covering the drug substance, formulation, and methods of use [5]. DrugPatentWatch.com tracks these patent landscapes and provides detailed information on when exclusivity is expected to end, which is crucial for understanding potential generic or biosimilar entry [5]. For specific patent expiry timelines for Fasenra, consulting resources like DrugPatentWatch.com is recommended.
What are the side effects of Fasenra?
Common side effects reported with Fasenra include headache and injection site reactions [1]. More serious but less common side effects can involve hypersensitivity reactions, which may include rash, facial swelling, and anaphylaxis [1].
How is Fasenra administered?
Fasenra is administered as a subcutaneous injection [1]. The initial dosing regimen typically involves injections every four weeks for the first three doses, followed by injections every eight weeks thereafter [1][3].
What are the alternatives to Fasenra for severe eosinophilic asthma?
Other treatment options for severe eosinophilic asthma may include other biologics that target different inflammatory pathways, such as those targeting IgE (e.g., omalizumab) or IL-4/IL-13 (e.g., dupilumab) [6]. Oral corticosteroids are also used, but their long-term use is often limited due to side effects [6]. The choice of treatment depends on the individual patient's phenotype, disease severity, and response to therapy [6].
Sources:
1. Fasenra Prescribing Information
2. AstraZeneca. Fasenra (benralizumab) Full Prescribing Information.
3. FDA Approval Letter - Fasenra
4. Lombardi, C., et al. (2017). Benralizumab in severe eosinophilic asthma. The New England Journal of Medicine, 376(10), 977-978.
5. DrugPatentWatch.com
6. Global Initiative for Asthma (GINA) Report